Get the Stockscreener App
73.29
1.31%
-0.85
Overview
News
Price History
Option Chain
Financials
Why ALC Down?
Discussions
Forecast
Dividend History
Alcon Inc stock is traded at $73.29, with a volume of 92,347.
It is down -1.31% in the last 24 hours and down -13.03% over the past month.
Alcon is one of the leading visioncare companies in the world. Following nine years as a Novartis subsidiary, it was spun off as a public company in April 2019. Alcon operates in two segments: visioncare and surgical. Visioncare comprises contact lenses, lenscare solutions, and a suite of ocular health products. With brands like Dailies, Total1, and Air Optix, Alcon controls about one fourth of the US contact lens market. Surgical comprises intraocular lenses, ophthalmic surgical equipment, and consumables used during surgeries. Its main products include Centurion, a phacoemulsification device used during cataract surgeries, and a portfolio of IOLs including PanOptix and Vivity. Alcon has one of the largest installed bases of eye surgical equipment in the world.
See More
Previous Close:
$74.14
Open:
$73.8
24h Volume:
92,347
Relative Volume:
0.06
Market Cap:
$35.69B
Revenue:
$10.40B
Net Income/Loss:
$980.00M
P/E Ratio:
37.11
EPS:
1.9749
Net Cash Flow:
$1.61B
1W Performance:
-5.93%
1M Performance:
-13.03%
6M Performance:
-2.44%
1Y Performance:
-20.77%
1-Day Range:
$73.12
$73.80
1-Week Range:
$73.17
$77.01
52-Week Range:
$71.55
$99.20
Alcon Inc Stock (ALC) Company Profile
Name
Alcon Inc
Sector
Industry
Phone
-
Address
-
Compare ALC vs ISRG, BDX, MDLN, RMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ALC
Alcon Inc
|
73.23 | 36.14B | 10.40B | 980.00M | 1.61B | 1.9749 |
ISRG
Intuitive Surgical Inc
|
471.56 | 169.79B | 10.06B | 2.88B | 2.49B | 7.876 |
BDX
Becton Dickinson Co
|
155.08 | 44.44B | 21.92B | 1.76B | 2.63B | 6.1223 |
MDLN
Medline Inc
|
41.86 | 34.48B | 28.43B | 1.16B | 1.26B | 1.4457 |
RMD
Resmed Inc
|
225.47 | 33.21B | 5.40B | 1.49B | 1.78B | 10.12 |
Alcon Inc Stock (ALC) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Feb-26-26 | Upgrade | Wells Fargo | Equal Weight → Overweight |
| Jan-30-26 | Initiated | William Blair | Mkt Perform |
| Jan-20-26 | Upgrade | Deutsche Bank | Hold → Buy |
| Jan-09-26 | Downgrade | Stifel | Buy → Hold |
| Dec-11-25 | Downgrade | BofA Securities | Buy → Underperform |
| Aug-21-25 | Downgrade | JP Morgan | Overweight → Neutral |
| May-20-25 | Downgrade | Deutsche Bank | Buy → Hold |
| May-14-25 | Reiterated | BTIG Research | Buy |
| Mar-28-25 | Reiterated | Needham | Buy |
| Mar-25-25 | Upgrade | BofA Securities | Neutral → Buy |
| Jan-24-25 | Reiterated | Needham | Buy |
| Jan-10-25 | Upgrade | Redburn Atlantic | Neutral → Buy |
| Dec-17-24 | Reiterated | Needham | Buy |
| Nov-12-24 | Reiterated | Needham | Buy |
| Oct-10-24 | Upgrade | Redburn Atlantic | Sell → Neutral |
| Sep-10-24 | Upgrade | RBC Capital Mkts | Sector Perform → Outperform |
| Jul-15-24 | Upgrade | Morgan Stanley | Underweight → Equal-Weight |
| May-15-24 | Upgrade | Oppenheimer | Perform → Outperform |
| Apr-10-24 | Initiated | Goldman | Buy |
| Mar-14-24 | Initiated | RBC Capital Mkts | Sector Perform |
| Feb-06-24 | Resumed | KeyBanc Capital Markets | Overweight |
| Jan-23-24 | Initiated | Bernstein | Outperform |
| Dec-18-23 | Downgrade | Redburn Atlantic | Neutral → Sell |
| Dec-12-23 | Initiated | Stifel | Buy |
| Dec-04-23 | Downgrade | Morgan Stanley | Equal-Weight → Underweight |
| Aug-17-23 | Upgrade | JP Morgan | Neutral → Overweight |
| May-30-23 | Resumed | Morgan Stanley | Equal-Weight |
| May-10-23 | Upgrade | Robert W. Baird | Neutral → Outperform |
| Mar-01-23 | Upgrade | Societe Generale | Sell → Hold |
| Dec-22-22 | Initiated | Mizuho | Buy |
| Nov-17-22 | Downgrade | Societe Generale | Hold → Sell |
| Aug-11-22 | Downgrade | Societe Generale | Buy → Hold |
| May-13-22 | Resumed | Credit Suisse | Outperform |
| May-12-22 | Upgrade | Stephens | Equal-Weight → Overweight |
| Apr-08-22 | Initiated | Needham | Buy |
| Mar-11-22 | Initiated | BofA Securities | Buy |
| Jan-18-22 | Downgrade | Stephens | Overweight → Equal-Weight |
| Jan-07-22 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Oct-01-21 | Initiated | Oppenheimer | Perform |
| Jul-14-21 | Initiated | Deutsche Bank | Buy |
| May-06-21 | Upgrade | Citigroup | Sell → Neutral |
| Mar-22-21 | Upgrade | BTIG Research | Neutral → Buy |
| Nov-12-20 | Downgrade | Guggenheim | Buy → Neutral |
| Jul-06-20 | Downgrade | Citigroup | Neutral → Sell |
| Jul-06-20 | Initiated | KeyBanc Capital Markets | Sector Weight |
| Jun-16-20 | Upgrade | Guggenheim | Neutral → Buy |
| Apr-08-20 | Downgrade | Robert W. Baird | Outperform → Neutral |
| Mar-26-20 | Upgrade | Argus | Hold → Buy |
| Mar-24-20 | Upgrade | Societe Generale | Sell → Hold |
| Mar-13-20 | Upgrade | UBS | Neutral → Buy |
| Mar-05-20 | Initiated | Citigroup | Neutral |
| Feb-26-20 | Upgrade | Berenberg | Hold → Buy |
| Jan-08-20 | Initiated | Argus | Hold |
| Oct-29-19 | Initiated | Stephens | Equal-Weight |
| Aug-21-19 | Reiterated | BofA/Merrill | Neutral |
| Jun-24-19 | Initiated | SVB Leerink | Mkt Perform |
| Jun-14-19 | Initiated | BTIG Research | Neutral |
| May-10-19 | Initiated | Robert W. Baird | Outperform |
| May-02-19 | Initiated | Credit Suisse | Outperform |
View All
Alcon Inc Stock (ALC) Latest News
BTIG Reiterates 'Buy' Rating for Alcon (ALC) with $92 Price Targ - GuruFocus
US LASIK Treatment Market Set to Witness Rapid Growth Through - openPR.com
Alcon Inc. stock faces steady demand amid eye care sector shifts and portfolio updates - AD HOC NEWS
Is It Time To Reassess Alcon (SWX:ALC) After A 26.9% Share Price Slide? - Yahoo Finance
Lensar stock slumps after hours on ending merger deal with Alcon over FTC pushback - MSN
STAAR Surgical Co stock faces acquisition scrutiny as Alcon deal advances amid analyst caution - AD HOC NEWS
Guidance Update: Should I invest in Alcon Inc before earnings2026 Top Decliners & Comprehensive Market Scan Insights - baoquankhu1.vn
Alcon Inc stock faces pressure amid terminated LENSAR merger and market downturn - AD HOC NEWS
Alcon Inc. stock faces headwinds amid surgical slowdown and tariff risks in eye care sector - AD HOC NEWS
Alcon, LENSAR abandon proposed merger amidst FTC pushback - Ophthalmology Times
Alcon Inc. stock gains momentum as AlphaValue upgrades rating to Buy amid eye care sector resilience - AD HOC NEWS
ALC Stock Price, Quote & Chart | ALCON INC (NYSE:ALC) - ChartMill
Lensar agrees to terminate sale to Alcon - MSN
Systane Eye Drops Lead Alcon's Shift to Organic Growth After Lensar Deal Collapse - AD HOC NEWS
Alcon and Lensar terminate proposed merger after FTC pressure - Eyes On Eyecare
EV Market: Can Alcon Inc outperform in the next rally2026 Price Targets & Long-Term Growth Stock Strategies - baoquankhu1.vn
Alcon And LENSAR: Why The Broken Merger Creates Two Different Buy Cases (NYSE:ALC) - Seeking Alpha
Alcon and Lensar Agree to Terminate Merger Agreement - VisionMonday.com
BTIG upgrades Lensar stock rating to buy after Alcon deal ends - Investing.com Canada
ACQUISITIONS & MERGERS NEWS: FTC successfully blocks Alcon-LENSAR merger in cataract surgery laser market - VitalLaw.com
BTIG upgrades Lensar stock rating to buy after Alcon deal ends By Investing.com - Investing.com South Africa
Alcon Drops $430M Lensar Deal Under Pressure From FTC - Law360
Alcon abandons effort to purchase LENSAR after FTC scrutiny - MedTech Dive
LENSAR Terminates Merger Agreement with Alcon Following FTC Challenge, Retains $10M Deposit and Announces Strategic Update - Minichart
Lensar Share Slide on Terminated Merger Deal With Alcon - marketscreener.com
Alcon, LENSAR terminate merger agreement after US FTC opposition - MLex
Alcon, LENSAR Halt Merger Deal Amid FTC Scrutiny - Medical Product Outsourcing
US FTC stops proposed merger of Alcon, LENSAR - MLex
US FTC Says It Stops Proposed Merger Of Cataract-Surgery Device Makers Lensar And Alcon - TradingView
LENSAR Stock Plunges—Alcon Scraps Merger After Prolonged Regulatory Review - Benzinga
LENSAR Stock Plunges—Alcon Scraps Merger After Prolonged Regulatory Review - Benzinga
LENSAR Ends Alcon Merger, Plans Strategic Update - TipRanks
Lensar and Alcon Sign Termination Agreement; Lensar Retains $10 Million Deposit - TradingView
LENSAR (NASDAQ: LNSR) terminates Alcon merger, retains $10M and plans strategy update - Stock Titan
Alcon Inc stock terminates Lensar merger amid US regulatory hurdles, shifts focus to core growth - AD HOC NEWS
Lensar to terminate Alcon merger agreement - Yahoo Finance
Switzerland: Alcon and Lensar agree to terminate merger agreement - Investors in Healthcare
Switzerland's Alcon Abandons Lensar Deal as US Antitrust Hurdles Persist - marketscreener.com
Alcon terminates LENSAR acquisition after FTC opposition By Investing.com - Investing.com Australia
Lensar, Alcon terminate merger after FTC opposition By Investing.com - Investing.com Canada
Alcon Buy Rating Reaffirmed, Despite Failed STAAR Merger, As Eyecare Portfolio Leads - Seeking Alpha
Alcon, LENSAR agree to terminate merger agreement - MLex
Lensar Stock Slumps After Hours On Ending Merger Deal With Alcon Over FTC Pushback - Stocktwits
LENSAR Announces Termination of Merger Agreement with Alcon Research - citybiz
Alcon (ALC) and Lensar Call Off Merger Agreement - GuruFocus
Alcon (ALC) Ends Merger Talks with Lensar, Impacting Both Stocks - GuruFocus
Lensar (LNSR) and Alcon (ALC) Terminate Merger Agreement Amid FT - GuruFocus
Lensar, Alcon terminate merger after FTC opposition - Investing.com
Lensar announces termination of merger agreement with Alcon Research, LLC - marketscreener.com
Alcon terminates LENSAR acquisition after FTC opposition - Investing.com
Lensar® Announces Termination Of Merger Agreement With Alcon Research, Llc - TradingView
Alcon Inc Stock (ALC) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.29%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):